


## CB2R/FAAH modulator-1

|                           |   |
|---------------------------|---|
| <b>Cat. No.:</b>          | HY-152251   |
| <b>CAS No.:</b>           | 928892-60-8   |
| <b>Molecular Formula:</b> | C <sub>24</sub> H <sub>27</sub> NO <sub>2</sub>   |
| <b>Molecular Weight:</b>  | 361.48  |
| <b>Target:</b>            | Cannabinoid Receptor; FAAH  |
| <b>Pathway:</b>           | GPCR/G Protein; Neuronal Signaling; Metabolic Enzyme/Protease                             |
| <b>Storage:</b>           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

|                                     |   |                                      |                                    |                                    |
|-------------------------------------|---|--------------------------------------|------------------------------------|------------------------------------|
| <b>Description</b>                  | CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with K <sub>i</sub> s of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC <sub>50</sub> of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production <sup>[1]</sup> . |                                      |                                    |                                    |
| <b>IC<sub>50</sub> &amp; Target</b> | CB2R<br>14.8 nM (K <sub>i</sub> )   | CB2R<br>123.6 nM (EC <sub>50</sub> ) | CB1R<br>241.3 nM (K <sub>i</sub> ) | CB1R<br>489 nM (EC <sub>50</sub> ) |
| <b>In Vitro</b>                     | CB2R/FAAH modulator-1 (compound 13; 10 μM; 24 h) decreases the pro-inflammatory cytokines TNFα, IFN-γ, IL-1β, and IL6 production in unstimulated monocytes and macrophages <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.  |                                      |                                    |                                    |

### REFERENCES

[1]. Francesca Intranuov, et al. Development of N-(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase. J Med Chem. 2023 Jan 12;66(1):235-250.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA